serum neurofilament light chain as an early disease biomarker in attr amyloidosis
Published 4 weeks ago • 25 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:41
the importance of early diagnosis for improved light chain amyloidosis survival
-
1:09
comparison of the simoa and msd r-plex assays to assess serum nfl levels in attr amyloidosis
-
2:19
using ai to predict light chain amyloidosis in patients with mgus and smm
-
1:09
the clinical features of pulmonary light chain amyloidosis
-
1:55
quantifying biomarkers on lambda amyloidogenic light chains to diagnose al amyloidosis
-
4:51
the current frontline treatment strategy in multiple myeloma
-
9:22
myeloma:interpreting test results | bmj learning
-
3:26
black blood small vessels
-
3:32
evaluating serum free light chain ratio as a biomarker for progression to multiple myeloma
-
1:38
diagnostic and clinical impact of the revised definition of light chain mgus
-
11:34
neurofilament light chain: a new candidate biomarker in hattr amyloidosis
-
0:53
neurofilament light chain as a biomarker in pediatric ms
-
1:51
diagnosis and potential therapeutic options for aa amyloidosis
-
2:31
cael-101: a monoclonal antibody therapy for al amyloidosis
-
3:01
novel promising agents and clinical trials in amyloidosis
-
1:56
light chain glycosylation provides diagnostic clues in cad
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:52
serum free light chain testing and international guidelines
-
1:31
chitinase 3–like 1 and neurofilament light chain in csf and cns atrophy in ms
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:00:21
light chain al amyloidosis diagnosis and treatment